Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanna Finocchiaro

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Expert Opinion on Medical Diagnostics|March 16, 2013
EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?Giovanna Finocchiaro, Luca Toschi, Isabella Garassino, et al.
Clinical Lung Cancer|November 27, 2018
Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase InhibitorsSabrina Rossi, Luca Toschi, Giovanna Finocchiaro, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2014
Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancerFederico Cappuzzo, Giovanna Finocchiaro, Francesco Grossi, et al.
Biomedicines|February 27, 2026
<i>PIK3CA</i> Alterations in NSCLC: Clinical Characteristics of a "Neglected" Population of Oncogene-Addicted PatientsSabrina Rossi, Arianna Pagliaro, Silvia Masini, et al.
Plos One|June 28, 2016
Outcome Evaluation of Oligometastatic Patients Treated with Surgical Resection Followed by Hypofractionated Stereotactic Radiosurgery (HSRS) on the Tumor Bed, for Single, Large Brain MetastasesFederico Pessina, Pierina Navarria, Luca Cozzi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 3, 2007
EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)Federico Cappuzzo, Claudia Ligorio, Claudio Ligorio, et al.
Future Oncology (London, England)|November 12, 2019
Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancerSabrina Rossi, Giovanna Finocchiaro, Vincenzo Di Noia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trialFederico Cappuzzo, Claudia Ligorio, Pasi A Jänne, et al.
Plos One|April 17, 2014
Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage diseaseLuca Toschi, Giovanna Finocchiaro, Teresa T Nguyen, et al.
Cancers|January 23, 2024
The Smokers Health Multiple ACtions (SMAC-1) Trial: Study Design and Results of the Baseline RoundAlberto Antonicelli, Piergiorgio Muriana, Giovanni Favaro, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Expert Opinion on Medical Diagnostics|March 16, 2013
EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?Giovanna Finocchiaro, Luca Toschi, Isabella Garassino, et al.
Clinical Lung Cancer|November 27, 2018
Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase InhibitorsSabrina Rossi, Luca Toschi, Giovanna Finocchiaro, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2014
Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancerFederico Cappuzzo, Giovanna Finocchiaro, Francesco Grossi, et al.
Biomedicines|February 27, 2026
<i>PIK3CA</i> Alterations in NSCLC: Clinical Characteristics of a "Neglected" Population of Oncogene-Addicted PatientsSabrina Rossi, Arianna Pagliaro, Silvia Masini, et al.
Plos One|June 28, 2016
Outcome Evaluation of Oligometastatic Patients Treated with Surgical Resection Followed by Hypofractionated Stereotactic Radiosurgery (HSRS) on the Tumor Bed, for Single, Large Brain MetastasesFederico Pessina, Pierina Navarria, Luca Cozzi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 3, 2007
EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)Federico Cappuzzo, Claudia Ligorio, Claudio Ligorio, et al.
Future Oncology (London, England)|November 12, 2019
Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancerSabrina Rossi, Giovanna Finocchiaro, Vincenzo Di Noia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trialFederico Cappuzzo, Claudia Ligorio, Pasi A Jänne, et al.
Plos One|April 17, 2014
Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage diseaseLuca Toschi, Giovanna Finocchiaro, Teresa T Nguyen, et al.
Cancers|January 23, 2024
The Smokers Health Multiple ACtions (SMAC-1) Trial: Study Design and Results of the Baseline RoundAlberto Antonicelli, Piergiorgio Muriana, Giovanni Favaro, et al.
Pageof 5